Contractile effects of angiotensin peptides in rat aorta are differentially dependent on tyrosine kinase activity

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 2, Issue 3, 2001, Pages 180-187

  Petrescu, Gheorghe ^a   Costuleanu, Marcel ^a   Slatineanu, Simona Mihaela ^a   Costuleanu, Natalia ^a   Foia, Liliana ^a   Costuleanu, Angela ^a  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Angiotensin I; Angiotensin II; Angiotensin III; Angiotensin IV; Aorta; Rat; Tyrosine kinase activity

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN DERIVATIVE; ANGIOTENSIN RECEPTOR; CALCIUM CHANNEL BLOCKING AGENT; DAIDZEIN; ENZYME INHIBITOR; GENISTEIN; ISOFLAVONE DERIVATIVE; NIFEDIPINE; PEPTIDE FRAGMENT; POTASSIUM; PROTEIN TYROSINE KINASE; SARALASIN; VASOCONSTRICTOR AGENT;

ANIMAL; AORTA; ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; ELECTROPHYSIOLOGY; IN VITRO STUDY; MALE; METABOLISM; PHYSIOLOGY; RAT; WISTAR RAT;

ANGIOTENSINS; ANIMALS; AORTA; CALCIUM CHANNEL BLOCKERS; ELECTROPHYSIOLOGY; ENZYME INHIBITORS; GENISTEIN; ISOFLAVONES; MALE; NIFEDIPINE; PEPTIDE FRAGMENTS; POTASSIUM; PROTEIN-TYROSINE KINASES; RATS; RATS, WISTAR; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; SARALASIN; VASOCONSTRICTOR AGENTS;

EID: 0035469334     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2001.025     Document Type: Article

References (56)

1. Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 2000;52:639-72.
2. Prescott G, Silversidis DW, Chiu SML, Reudelhuber TL. Contribution of circulating renin to local synthesis of angiotensin peptides in the heart. Physiol Genomics 2000;4:67-73.
3. Saris JJ, van Dijk MA, Kroon I, Schalekamp MADH, Danser AHJ. Functional importance of angiotensin-converting enzyme-dependent in situ angiotensin II generation in the human forearm. Hypertension 2000;35:764-8.
4. Andre P, Schott C, Nehlig H, Stoclet JC. Aortic smooth muscle cells are able to convert angiotensin I to angiotensin II. Biochim Biophys Res Commun 1990;173(3):1137-42.
5. Robertson MJ, Cunoosamy MP, Clark KL. Effects of peptidase inhibition on angiotensin receptor agonist and antagonist potency in rabbit isolated thoracic aorta. Br J Pharmacol 1992;106(1):166-72.
6. Cheng DY, Dewitt BJ, Dent EL, Nossaman BD, Kadowitz PJ. Analysis of response to angiotensin IV in the pulmonary vascular bed of the cat. Eur J Pharmacol 1994;261(1-2):223-7.
7. Li Q, Zhang J, Pfaffendorf M, van Zwieten PA. Comparative effects of angiotensin II and its degradation products angiotensin III and angiotensin IV in rat aorta. Br J Pharmacol 1995;116(7):2963-70.
8. Nossaman BD, Feng CJ, Kaye AD, Kadowitz PJ. Analysis of responses to ANG IV: effect of PD-123319 and DuP-753 in the pulmonary circulation of the rat. Am J Physiol (Lung Cell Mol Physiol 12) 1995;268(2Ptl):L302-L308.
9. Ferrario CM, Iyer SN. Angiotensin-(1-7): a bioactive fragment of the renin-angiotensin system. Regul Pept 1998;78(1-3):13-18.
10. Catt KJ. Angiotensin II receptors. In The renin-angiotensin system. ed. Robertson JS & Nicholls MG pp. 12.1-12.4. London-New York: Gower Medical Publishing, 1993.
11. Chaki S, Inagami T. Identification and characterization of a new binding site for angiotensin II in mouse neuroblastoma neuro-2A cells. Biochem Biophys Res Commun 1992;182(1): 388-94.
12. Näveri L. The role of receptor subtypes in cerebrovascular regulation in the rat. Acta Physiol Scand 1995;155(suppl 630):1-48.
13. Nickenig G, Geisen G, Vetter H, Sachiniadis A. Characterization of angiotensin receptors on human skin fibroblasts. J Mol Med 1997;75(3):217-22.
14. Chen L, McNeill JR, Wilson TW, Gopalakrishnan V. Heterogeneity in vascular smooth muscle responsiveness to angiotensin II. Role of endothelin. Hypertension 1995;26(1):83-8.
15. Alexander RW, Brock TA, Gimbrone MA, Rittenhouse SL. Angiotensin II increases inositol triphosphate and calcium in vascular smooth muscle cells. Hypertension 1985;7(3Ptl):447-51.
16. Berridge MJ. Inositol trisphosphatc and calcium signalling. Nature 1993;361(6410):315-25.
17. Marrero MB, Schieffer B, Bernstein KE, Ling BN. Angiotensin II-induced tyrosine phosphorylations in mesangial and vascular smooth muscle cells. Clin Experim Pharmacol Physiol 1996;23(1):83-8.
18. Di Salvo J, Steusloff A, Semenchuk L, Satoh S, Kolquist K, Pfitzer G. Tyrosine kinase inhibitors suppress agonist-induced contraction in smooth muscle. Biochem Biophys Res Commun 1993;190(3):968-74.
19. Laniyonu AA, Saifeddine M, Yang S-G, Hollenberg MD. Tyrosine kinase inhibitors and the contractile action of G-protein-linked vascular agonists. Can J Physiol Pharmacol 1994;72(9):1075-85.
20. Huckle WR, Dy RC, Earp HS. Calcium-dependent increase in tyrosine-kinase activity stimulated by angiotensin II. Proc Natl Acad Sci USA 1992;89(18):8837-41.
21. Timmermans PBMWM, Wong PC, Chiu AT et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993;45(2):205-51.
22. Stroth U, Unger T. The renin-angiotensin system and its receptors. J Cardiovasc Pharmacol 1999;33(suppl 1):S21-S28.
23. Moore AF, Hall HM, Khairallah PA. A comparison of the effects of angiotensin II and heptapeptide on smooth muscle (vascular and uterine). Eur J Pharmacol 1976;39(1):101-07.
24. Catalioto RM, Porchia R, Renzetti AR, Criscuoli M, Subissi A, Giachetti A. Angiotensin II-induced responses in vascular smooth muscle cells: inhibition by non-peptide receptor antagonists. Eur J Pharmacol 1995;280(3):285-92.
25. 4 and their functions. Regul Pept 1995;59(3):269-95.
26. Sim MK. Degradation of angiotensin I in the endothelium and smooth muscle of the rat aorta. Biochem Pharmacol 1993;45(7):1524-7.
27. 4 receptor subtypes. Regul Pept 1997;68(2):131-8.
28. Brailoiu E, Todiras M, Margineanu A et al. TLC characterization of liposomes containing angiotensinogen, angiotensine I, angiotensine II and saralazin. Biomed Chromatogr 1997;11(3):160-3.
29. Griendling KK, Ushio-Fukai M, Lassègue B, Alexander RW. Angiotensin II signaling in vascular smooth muscle. New concepts. Hypertension 1997;29(1Pt2): 366-73.
30. Tsunoda Y. Receptor-operated calcium influx mediated by protein tyrosine kinase pathways. J Recept Sign Transduct Res 1998;18(4-6):281-310.
31. 2+-dependent action potentials in cultured smooth muscle cells. Eur J Pharmacol 1990;187(2):183-91.
32. Gunther S, Gimbrone RA, Alexander RW. Identification and characterization of the high affinity vascular angiotensin II receptor in rat mesenteric artery. Circ Res 1980;47(2):278-86.
33. Moore GJ. Designing peptide mimetics. Trends Pharmacol Sci 1994;15(4):124-9.
34. Chang RSL, Lotti VJ. Angiotensin receptor subtypes in rat, rabbit and monkey tissues: relative distribution and species dependency. Life Sci 1991;49(20):1485-90.
35. Patel JM, Martens JR, Li YD, Gelband CH, Raizada MK, Block ER. Angiotensin IV receptor-mediated activation of lung endothelial NOS is associated with vasorelaxation. Am J Physiol (Lung Cell Mol Physiol 19) 1998;275(6Ptl):L1061-L1068.
36. Swanson GN, Hanesworth JM, Sardinia MF et al. Discovery of a distinct binding site for angiotensin II (3-8), a putative angiotensin IV receptor. Regul Pept 1992;40(3):409-19.
37. Hall KL, Hanesworth JM, Ball AE, Felgenhauer GP, Hosick HL, Harding JW. Identification and characterization of a novel angiotensin binding site in cultured vascular smooth muscle cells that is specific for the hexapeptide (3-8) fragments of angiotensin II, angiotensin IV. Regul Pept 1993;44(2):225-32.
38. Nishizuka Y. The role of protein kinase C in cell surface signal transduction and tumour promotion. Nature 1984; 308(5961):693-8.
39. Meloche S, Landry J, Huot J, Houle F, Marceau F, Giasson E. p38 MAP kinase pathway regulates angiotensin II-induced contraction of rat vascular smooth muscle. Am J Physiol 2000;79;741-51.
40. Eguchi S, Iwasaki H, Inagami T et al. Involvement of PYK2 in angiotensin II signaling of vascular smooth muscle cells. Hypertension 1999;33(1Pt2):201-6.
41. 2+-channel current in vascular smooth muscle cells is inhibited by lavendustin-A and LY-294002. Pflugers Arch 1999;437(3):317-23.
42. Ushio-Fukai M, Alexander RW, Akers M, Lyons PR, Lassègue B, Griendling KKAngiotensin II receptor coupling to phospholipase D is mediated by the βγ subunits of heterotrimeric G proteins in vascular smooth muscle cells. Mol Pharmacol 1999; 55(1):142-9.
43. Di Salvo J, Gifford D, Kokkinakis A. ATP-and polyphosphate-mediated stimulation of pp60c-src kinase activity in extracts from vascular smooth muscle. J Biol Chem 1989;264(10):10773-8.
44. Molloy CJ, Taylor DS, Weber H. Angiotensin II stimulation of rapid protein tyrosine phosphorylation and protein kinase activation in rat aortic smooth muscle cells. J Biol Chem 1993;268 (10):7338-45.
45. Berk BC. Angiotensin II signal transduction in vascular smooth muscle: pathways activated by specific tyrosine kinases. J Am Nephrol 1999;10(suppl 11):S62-68.
46. Yang S-G, Saifeddine M, Laniyonu A, Hollenberg MD. Distinct signal transduction pathways for angiotensin II in guinea pig gastric smooth muscle: differential blockade by indomethacin and tyrosine kinase inhibitors. J Pharmacol Exp Ther 1993;264(2): 958-66.
47. Akiyama T, Ishida J, Nakagawa S et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987;262(12):5592-5.
48. Hollenberg MD. Tyrosine kinase-mediated signal transduction pathways and the actions of polypeptide growth factors and G-protein-coupled agonists in smooth muscle. Mol Cell Biochem 1995;149/150:77-85.
49. Wijctunge S, Aalkjaer C, Schachter M, Hughes AD. Tyrosine kinase inhibitors block calcium channel currents in vascular smooth muscle cells. Biochem Biophys Res Commun 1992;189(3):1620-3.
50. Thomas WG. Regulation of angiotensin II type I (AT1) receptor function. Regul Pept 1999;79(1):9-23.
51. Leduc I, Haddad P, Giasson E, Meloche S. Involvement of a tyrosine kinase pathway in the growth-promoting effects of angiotensin II on aortic smooth muscle cells. Mol Pharmacol 1995;48(4):582-92.
52. Smith JB. Angiotensin-receptor signaling in cultured vascular smooth muscle cells. Am J Physiol 1986;250(5Pt2):F759-F769.
53. 2+ in relation to contractile responses of rat and guinea-pig aorta. Naunyn Schmiedebergs Arch Pharmacol 1991;344(1):107-13.
54. Kusaka M, Sperelakis N. Inhibition of L-type calcium current by genistein, a tyrosine kinase inhibitor, in pregnant rat myometrial cells. Biochim Biophys Acta 1995;1240(2):196-200.
55. 2+ entry by tyrosine kinase inhibitors. J Biol Chem 1993;268(14):9945-8.
56. 2+ entry in human platelets. FEBS Lett 1993;315(13):242-6.